Fanconi Anemia NGS Panel
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000506555.10
- Last updated: 2023-08-22
- Test version history
- 506555.10, last updated: 2023-08-22
- 506555.9, last updated: 2017-08-25
- 506555.8, last updated: 2016-05-13
- 506555.7, last updated: 2015-09-01
- 506555.6, last updated: 2014-07-02
- 506555.5, last updated: 2014-06-17
- 506555.4, last updated: 2014-06-13
- 506555.3, last updated: 2014-05-30
- 506555.2, last updated: 2014-04-07
- 506555.1, last updated: 2014-04-07
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Familial cancer of breast
Offered by Fulgent Genetics
- USPSTF, 2019Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
- USPSTF, 2013Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
- NCI PDQ, Breast and Gynecologic CancersGenetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version
- NCI PDQ, Cancer Genetics CounselingCancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version
- NCCN, 2023Breast Cancer, NCCN Guidelines Version 4.2022
- NCCN, 2022NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
- NICE, 2019UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019
- ACMG ACT, 2019American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019
- OMIM
- View AKT1 variations in ClinVar
- View ATM variations in ClinVar
- View BARD1 variations in ClinVar
- View BRCA1 variations in ClinVar
- View BRCA2 variations in ClinVar
- View CASP8 variations in ClinVar
- View CDH1 variations in ClinVar
- View ESR1 variations in ClinVar
- View HMMR variations in ClinVar
- View KRAS variations in ClinVar
- View NQO2 variations in ClinVar
- View SLC22A18 variations in ClinVar
- View PHB1 variations in ClinVar
- View PIK3CA variations in ClinVar
- View RAD51 variations in ClinVar
- View TP53 variations in ClinVar
- View XRCC3 variations in ClinVar
- View RAD54L variations in ClinVar
- View PPM1D variations in ClinVar
- View RB1CC1 variations in ClinVar
- View BRIP1 variations in ClinVar
- RefSeqGene
- Coriell Institute for Medical Research
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.